6533b81ffe1ef96bd1278b00

RESEARCH PRODUCT

Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment

J. SmorenburgM. De GraafJ. Van StraalenA. ConsolaroA. BelotE. AlexeevaV. VargovaR. ConsoliniM. C. MaggioD. RiganteR. AbdwaniA. L. Rodriguez LozanoI. OrbanN. RupertoN. WulffraatS. De RoockJ. Swart

subject

Settore MED/38 - Pediatria Generale E SpecialisticaDMARDs juvenile idiopathic arthritis Dermatologic adverse events

description

Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.

yearjournalcountryeditionlanguage
2020-01-01
http://hdl.handle.net/10447/464221